Collplant Biotechnologies Ltd (CLGN)

Currency in USD
1.70
+0.02(+1.19%)
Real-time Data·
CLGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.701.70
52 wk Range
1.304.98
Key Statistics
Prev. Close
1.68
Open
1.7
Day's Range
1.7-1.7
52 wk Range
1.3-4.98
Volume
747
Average Volume (3m)
26.57K
1-Year Change
-55.0265%
Book Value / Share
0.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.56
Upside
+580.00%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Collplant ADR Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company’s products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Collplant Biotechnologies Ltd Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.34 missed forecast of -$0.275; revenue of $164,000 fell short of $432,000 expectation
  • Full-year revenue decreased to $515,000 from $11 million in 2023; net loss of $16.6 million or $1.45 per share
  • Stock price declined 0.68% to $2.78, near 52-week low; analysts maintain $14 price target
  • Company focuses on expanding Virgenix STR distribution in Europe and Asia; optimizing regenerative breast implants
  • Cash position expected to last through Q2 2026; $2 million payment received from AbbVie in February 2025
Last Updated: 26/03/2025, 14:50
Read Full Transcript

Compare CLGN to Peers and Sector

Metrics to compare
CLGN
Peers
Sector
Relationship
P/E Ratio
−1.8x−1.6x−0.6x
PEG Ratio
−0.060.230.00
Price/Book
2.3x3.0x2.6x
Price / LTM Sales
8.7x3.4x3.3x
Upside (Analyst Target)
-611.6%45.0%
Fair Value Upside
Unlock15.9%6.5%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.56
(+580.00% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 26, 2025
EPS / Forecast
-0.25 / 0.16
Revenue / Forecast
80.00K / 2.76M
EPS Revisions
Last 90 days

People Also Watch

0.171
NCL
-3.87%
0.902
XTLB
+7.78%
0.7602
SVRE
+1.52%
0.38
NTCL
+5.67%
63.32
MKCv
0.00%

FAQ

What Is the Collplant ADR (CLGN) Share Price Today?

The live Collplant ADR share price today is 1.70

What Stock Exchange Does Collplant ADR (CLGN) Trade On?

Collplant ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Collplant ADR?

The stock symbol (also called a 'ticker') for Collplant ADR is "CLGN."

What Is the Current Collplant ADR Market Cap?

As of today, Collplant ADR market capitalisation is 21.46M.

What Is Collplant ADR's (CLGN) Earnings Per Share (TTM)?

The Collplant ADR EPS is currently -1.02 (Trailing Twelve Months).

When Is the Next Collplant ADR Earnings Date?

Collplant ADR's next earnings report will be released on 01 Apr 2026.

Is CLGN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Collplant ADR moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Collplant ADR Stock Split?

Collplant ADR has split 1 times. (See the CLGN stock split history page for full effective split date and price information.)

How Many Employees Does Collplant ADR Have?

Collplant ADR has 57 employees.

What is the current trading status of Collplant ADR (CLGN)?

As of 04 Feb 2026, Collplant ADR (CLGN) is trading at a price of 1.70, with a previous close of 1.68. The stock has fluctuated within a day range of 1.70 to 1.70, while its 52-week range spans from 1.30 to 4.98.

What Is Collplant ADR (CLGN) Price Target According to Analysts?

The average 12-month price target for Collplant ADR is USD11.56, with a high estimate of USD12 and a low estimate of USD11.12. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +580.00% Upside potential.

What Is the CLGN Premarket Price?

CLGN's last pre-market stock price is 1.79. The pre-market share volume is 10.00, and the stock has decreased by 0.11, or 6.55%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.